| First Author | Haake SM | Year | 2022 |
| Journal | JCI Insight | Volume | 7 |
| Issue | 15 | PubMed ID | 35763345 |
| Mgi Jnum | J:328897 | Mgi Id | MGI:7340732 |
| Doi | 10.1172/jci.insight.154098 | Citation | Haake SM, et al. (2022) Ligand-independent integrin beta1 signaling supports lung adenocarcinoma development. JCI Insight 7(15):e154098 |
| abstractText | Integrins - the principal extracellular matrix (ECM) receptors of the cell - promote cell adhesion, migration, and proliferation, which are key events for cancer growth and metastasis. To date, most integrin-targeted cancer therapeutics have disrupted integrin-ECM interactions, which are viewed as critical for integrin functions. However, such agents have failed to improve cancer patient outcomes. We show that the highly expressed integrin beta1 subunit is required for lung adenocarcinoma development in a carcinogen-induced mouse model. Likewise, human lung adenocarcinoma cell lines with integrin beta1 deletion failed to form colonies in soft agar and tumors in mice. Mechanistically, we demonstrate that these effects do not require integrin beta1-mediated adhesion to ECM but are dependent on integrin beta1 cytoplasmic tail-mediated activation of focal adhesion kinase (FAK). These studies support a critical role for integrin beta1 in lung tumorigenesis that is mediated through constitutive, ECM binding-independent signaling involving the cytoplasmic tail. |
